InBody, Successfully Concludes '2022 BIA Symposium X Geungamsojeung'

Domestic and International Medical and Research Teams from Over 10 Departments Gathered in One Place

Lee Rami, CEO of InBody, is presenting at the '2022 BIA Symposium'.
[Photo by InBody]

[Asia Economy Reporter Lee Gwan-joo] Domestic medical professionals and experts gathered in one place to discuss research, prevention, and treatment methods for sarcopenia.

InBody recently announced on the 8th that it successfully concluded the '2022 BIA Symposium X Sarcopenia.' Now in its fifth year, the BIA Symposium is a forum to share research cases and discuss future tasks based on BIA (Bioelectrical Impedance Analysis), the fundamental principle of body composition measurement.

This time, the topic of sarcopenia was addressed, a condition characterized by a decrease in muscle mass leading to impaired motor function. If sarcopenia is left untreated, the reduction in basal metabolic rate makes managing chronic diseases difficult, potentially worsening diabetes and cardiovascular diseases.

The symposium began with an introduction of overseas clinical cases by Yasushi Ohashi, a researcher at Toho University Sakura Medical Center in Japan. He delivered a lecture on the clinical significance of diagnosing sarcopenia in nephrology using InBody from the perspective of body water. In particular, he introduced the close correlation between nutritional status and body composition, which greatly affects the cure rate and mortality of chronic kidney disease (CKD) patients.

Along with this, three sessions were held: ▲Setting evaluation tools for sarcopenia ▲Practical know-how based on clinical research and case studies on sarcopenia ▲Nutritional management and exercise intervention in sarcopenia. Lee Rami, CEO of InBody, served as a speaker in the first session, presenting that when using BIA, it is possible to quickly check basic muscle mass and whether muscle mass is overestimated in overhydration states through a simple method, suggesting the medical utility of BIA.

CEO Lee said, "As global interest in the use of InBody as a measurement device for diagnosing and treating sarcopenia is increasing, it is meaningful to hold an academic forum to discuss BIA-based sarcopenia research and case studies actively conducted in more than ten different fields and to share insights for improving patients' lives. Moving forward, we will strive to become a global academic society by sharing more diverse topics and research content, including overseas clinical indicator development research beyond domestic studies."

Result items derived from BIA technology such as skeletal muscle index, body fat percentage, extracellular water ratio, and phase angle are actively being introduced not only in sarcopenia but also in various research and clinical fields including kidney dialysis, breast cancer lymphedema, obesity, and nutrition. InBody, an advanced medical device using the BIA method, has been utilized in over 5,000 domestic and international papers, contributing to the advancement of medical technology and the healthy wellness life of people worldwide.

This content was produced with the assistance of AI translation services.